-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on ProKidney, Raises Price Target to $9

Benzinga·07/09/2025 16:09:56
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target from $6 to $9.